IL-12抗肿瘤临床研究进展

Progress in Antitumor Effect of Interleukin-12 in Clinical Studies

白介素-12(inlerleukin-12,IL-12)在临床前研究中显示出了较好的药效及安全性,随后展开了IL-12用于肿瘤治疗的临床研究。早期研究探索了给药方案、IL-12的最大耐受剂量和易感肿瘤。但因给药剂量大,给药次数频繁,其全身给药引起了严重的副作用。由于出现了严重的受试者死亡医疗事故,关于IL-12的临床研究被FDA停止。在经过了几年研究低迷之后,目前又恢复了对IL-12治疗潜力的研究,其给药策略在持续探索中。

Preclinical studies on interleukin-12(IL-12)have shown encouraging efficacy and safety.Subsequently,the clinical research of IL-12 in the treatment of tumor was carried out.Early studies have explored the administration regimen,the maximum tolerable dose of IL-12 and susceptible tumors.However,due to the large dosage and frequent administration,systemic administration of IL-12 caused serious side effects.Clinical studies on IL-12 were stopped by FDA due to serious medical accident of subject death.After the frustrations of the first few years,interest in the therapeutic potential of IL-12 has now revived and its drug delivery strategy is continuing to be explored.